Optimize the convenient dosing schedule of TREANDA to help patients benefit from therapy

Dose modification may help patients continue therapy and achieve treatment results

^*Dose re-escalation in the treatment of CLL in subsequent cycles may be considered at the discretion of the treating physician.
^†Clinically significant Grade 3 or greater toxicity.

^‡Treatment may be reinitiated at the discretion of the treating physician.

Continued toxicity despite dose modifications or certain severe reactions (see Warnings and Precautions in full Prescribing Information) may warrant discontinuation

Patients taking TREANDA were adherent to the dosing schedule¹

90% of patients taking TREANDA received the planned dose of TREANDA

95% of patients taking chlorambucil received the planned dose of chlorambucil

Indications

TREANDA is indicated for the treatment of patients with chronic lymphocytic leukemia (CLL). Efficacy relative to first-line therapies other than chlorambucil has not been established.

TREANDA is indicated for the treatment of patients with indolent B-cell non-Hodgkin’s lymphoma (NHL) that has progressed during or within 6 months of treatment with rituximab or a rituximab-containing regimen.

Important Safety Information

Serious adverse reactions, including myelosuppression, infections, infusion reactions and anaphylaxis, tumor lysis syndrome, skin reactions including SJS/TEN, other malignancies, and extravasation, have been associated with TREANDA. Some reactions, such as myelosuppression, infections, and SJS/TEN (when TREANDA was administered concomitantly with allopurinol and other medications known to cause SJS/TEN), have been fatal. Patients should be monitored closely for these reactions and treated promptly if any occur
Adverse reactions may require interventions such as decreasing the dose of TREANDA, or withholding or delaying treatment
TREANDA is contraindicated in patients with a known hypersensitivity to bendamustine or mannitol. Women should be advised to avoid becoming pregnant while using TREANDA
The most common non-hematologic adverse reactions associated with TREANDA (frequency ≥15%) were pyrexia, nausea, and vomiting. The most common hematologic abnormalities associated with TREANDA (frequency ≥15%) were anemia, thrombocytopenia, neutropenia, lymphopenia, and leukopenia

TO REPORT SIDE EFFECTS: Contact us at 1-800-896-5855 or usmedinfo@cephalon.com

Reference

Knauf WU, Lissichkov T, Aldaoud A, et al. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol. 2009;27:4378-4384.

Contact CORE: Cephalon Oncology Reimbursement Expertise for assistance and support

Here's your chance to share your story. Enroll Today!

Download the Pivotal CLL Trial

Comparing bendamustine to chlorambucil in previously untreated patients with CLL>>

This article is based upon the pivotal study that formed the basis for approval of TREANDA. The conclusions reached in this article are consistent with the TREANDA Prescribing Information, however, the article contains information that differs from the TREANDA Prescribing Information. Please review this article in conjunction with the accompanying full Prescribing Information.